Komatsu N - Search Results

1

The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells.

Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. Gery S, et al. Among authors: komatsu n. Mol Cell. 2006 May 5;22(3):375-82. doi: 10.1016/j.molcel.2006.03.038. Mol Cell. 2006. PMID: 16678109 Free article.

2

Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer.

Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, Marchevsky A, Mckenna R, Taguchi H, Koeffler HP. Gery S, et al. Among authors: komatsu n. Clin Cancer Res. 2007 Mar 1;13(5):1399-404. doi: 10.1158/1078-0432.CCR-06-1730. Clin Cancer Res. 2007. PMID: 17332281

3

SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP. Komatsu N, et al. Oncol Rep. 2006 Jan;15(1):187-91. Oncol Rep. 2006. PMID: 16328054

4

KLF6: mutational analysis and effect on cancer cell proliferation.

Yin D, Komatsu N, Miller CW, Chumakov AM, Marschesky A, McKenna R, Black KL, Koeffler HP. Yin D, et al. Among authors: komatsu n. Int J Oncol. 2007 Jan;30(1):65-72. Int J Oncol. 2007. PMID: 17143513

5

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.

Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP. Kumagai T, et al. Among authors: komatsu n. Int J Cancer. 2007 Aug 1;121(3):656-65. doi: 10.1002/ijc.22558. Int J Cancer. 2007. PMID: 17417771 Free article.

6

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.

Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H. Ikezoe T, et al. Among authors: komatsu n. Mol Cancer Ther. 2006 Oct;5(10):2522-30. doi: 10.1158/1535-7163.MCT-06-0071. Mol Cancer Ther. 2006. PMID: 17041096

7

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H. Ikezoe T, et al. Among authors: komatsu n. Mol Cancer Ther. 2007 Jun;6(6):1851-7. doi: 10.1158/1535-7163.MCT-07-0067. Epub 2007 May 31. Mol Cancer Ther. 2007. PMID: 17541033

8

CYR61: a new measure of lung cancer outcome.

Mori A, Desmond JC, Komatsu N, O'Kelly J, Miller CW, Legaspi R, Marchevsky AM, McKenna RJ Jr, Koeffler HP. Mori A, et al. Among authors: komatsu n. Cancer Invest. 2007 Dec;25(8):738-41. doi: 10.1080/02770900701512597. Cancer Invest. 2007. PMID: 18058471

9

Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells.

Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A. Nishioka C, et al. Among authors: komatsu n. Int J Cancer. 2009 Sep 1;125(5):1168-76. doi: 10.1002/ijc.24377. Int J Cancer. 2009. PMID: 19422044 Free article.

10

Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.

Nishioka C, Ikezoe T, Yang J, Takeshita A, Taniguchi A, Komatsu N, Togitani K, Koeffler HP, Yokoyama A. Nishioka C, et al. Among authors: komatsu n. Leuk Res. 2008 Jun;32(6):865-72. doi: 10.1016/j.leukres.2007.09.017. Epub 2007 Nov 5. Leuk Res. 2008. PMID: 17983653

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,027 results

Search Page